DENTSPLY SIRONA Inc. ("Dentsply Sirona") (Nasdaq: XRAY), today announced that its premier annual clinical education event for dental professionals is set to provide the most extensive offering of training...
Inogen's (INGN) second-quarter results benefit from higher revenues across its segments.
LHC Group's (LHCG) second-quarter results benefit from organic growth in both home health and hospice admissions.
DENTSPLY SIRONA's (XRAY) second-quarter results benefit from strong segmental performance.
Dentsply (XRAY) delivered earnings and revenue surprises of 9.23% and 6.95%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
-- Revenue increased 117.3% to $1,067 million. Organic revenue increased 104.6%
Let's see how Medical Product companies' stocks like BDX, RMD, CAH, ABMD and XRAY are poised ahead of their earnings releases.
DENTSPLY SIRONA (XRAY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
DENTSPLY SIRONA's (XRAY) second-quarter results are likely to reflect strong segmental performance.
Rebound in base sales makes us optimistic about HSIC, XRAY, GMED and ABC's results this time around.